Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue SUPPL. 2, 2004, Pages

  Nix, David E ^a   Majumdar, Anup K ^b   DiNubile, Mark J ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Carbapenems; Distribution; Excretion; Metabolism; Protein binding; Renal insufficiency

Indexed keywords

CARBAPENEM DERIVATIVE; CYTOCHROME P450; ERTAPENEM; GLYCOPROTEIN P; IMIPENEM; PROBENECID; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; PENICILLIN G;

ABDOMINAL INFECTION; ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FEMALE; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY METABOLISM; LIVER DISEASE; LIVER METABOLISM; MALE; MONOTHERAPY; NONHUMAN; OBESITY; PELVIC INFLAMMATORY DISEASE; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SKIN INFECTION; TISSUE DISTRIBUTION; URINARY EXCRETION; URINARY TRACT INFECTION; AGE; BODY WEIGHT; CHILD CARE; CLINICAL PRACTICE; DRUG FECES LEVEL; DRUG INDICATION; DRUG URINE LEVEL; DRUG USE; EUROPE; KIDNEY FAILURE; LICENSING; SKIN STRUCTURE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; KIDNEY FAILURE; LACTAMS; MALE; MIDDLE AGED;

EID: 3042637085     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh205     Document Type: Review

References (39)

1. Odenholt, I. (2001). Ertapenem: a new carbapenem. Expert Opinion on Investigational Drugs 10, 1157-66.
2. (2002). Ertapenem (Invanz) - a new parenteral carbapenem. Medical Letter on Drugs and Therapeutics 44, 25-6.
3. Shah, P. M. & Isaacs, R. D. (2003). Ertapenem, the first of a new group of carbapenems. Journal of Antimicrobial Chemotherapy 52, 538-42.
4. Goldstein, E. J., Citron, D. M., Merriam, C. V. et al. (2002). Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrobial Agents and Chemotherapy 46, 1136-40.
5. Livermore, D. M., Carter, M. W., Bagel, S. et al. (2001). In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrobial Agents and Chemotherapy 45, 1860-7.
6. Rolston, K. V., LeBlanc, B. M., Streeter, H. et al. (2002). In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagnostic Microbiology and Infectious Disease 43, 219-23.
7. Jimenez-Cruz, F., Jasovich, A., Cajigas, J. et al. (2002). A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 60, 16-22.
8. Pelak, B. A., Bartizal, K., Woods, G. L. et al. (2002). Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. Diagnostic Microbiology and Infectious Disease 43, 129-33.
9. Fuchs, P. C., Barry, A. L. & Brown, S. D. (2001). In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrobial Agents and Chemotherapy 45, 1915-18.
10. Goldstein, E. J., Citron, D. M., Vreni, M. C. et al. (2000). Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrobial Agents and Chemotherapy 44, 2389-94.
11. van Ogtrop, M., Andes, D. & Craig, W. A. (1999). In vivo antimicrobial activity of MK-0826, a new carbapenem against various penicillin-resistant pneumococci. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 1999. Abstract 999. p. American Society for Microbiology, Washington, DC.
12. Friedland, I., Mixson, L. A., Majundar, A. et al. (2002). In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. Journal of Chemotherapy 14, 483-91.
13. Graham, D. R., Lucasti, C., Malafaia, O. et al. (2002). Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Diseases 34, 1460-8.
14. Ortiz-Ruiz, G., Caballero-Lopez, J., Friedland, I. R. et al. (2002). A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clinical Infectious Diseases 34, 1076-83.
15. Craig, W.A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-10.
16. Craig, W. A. & Ebert, S. C. (1989). Protein binding and its significance in antibacterial therapy. Infectious Disease Clinics of North America 3, 407-14.
17. Muller, M., Muller-Zellenberg, U., Hochhaus, G. et al. (2001). Current concepts in pharmacokinetics and their implications for clinical medicine. Wiener Klinische Wochenschrift 113, 566-72.
18. Wise, R. (1986). The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clinical Pharmacokinetics 11, 470-82.
19. Bergan, T., Engeset, A. & Olszewski, W. (1987). Does serum protein binding inhibit tissue penetration of antibiotics? Reviews of Infectious Diseases 9, 713-18.
20. Benet, L. Z. & Hoener, B. A. (2002). Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology and Therapeutics 71, 115-21.
21. Legua, P., Lema, J., Moll, J. et al. (2002). Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clinical Therapeutics 24, 434-44.
22. Musson, D. G., Birk, K. L., Cairns, A. M. et al. (1998). High-performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749,345, in human plasma and urine. Journal of Chromatography B 720, 99-106.
23. Majumdar, A. K., Musson, D. G., Birk, K. L. et al. (2002). Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrobial Agents and Chemotherapy 46, 3506-11.
24. Meibohm, B., Beierle, I. & Derendorf, H. (2002). How important are gender differences in pharmacokinetics? Clinical Pharmacokinetics 41, 329-42.
25. Koch-Weser, J. & Sellers, E. M. (1976). Binding of drugs to serum albumin (first of two parts). New England Journal of Medicine 294, 311-6.
26. Rolinson, G. N. (1980). The significance of protein binding of antibiotics in antibacterial chemotherapy. Journal of Antimicrobial Chemotherapy 6, 311 -7.
27. Nix, D. E., Goodwin, S. D., Peloquin, C. A. et al. (1991). Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrobial Agents and Chemotherapy 35, 1953-9.
28. Nix, D. E., Goodwin, S. D., Peloquin, C. A. et al. (1991). Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrobial Agents and Chemotherapy 35, 1947-52.
29. Cars, O. (1990). Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scandinavian Journal of Infectious Diseases. Supplementum 74, 23-33.
30. Turnidge, J. D. (1998). The pharmacodynamics of β-lactams. Clinical Infectious Diseases 27, 10-22.
31. Cars, O. (1997). Efficacy of β-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagnostic Microbiology and Infectious Disease 27, 29-33.
32. Bailey, E. M., Rybak, M. J. & Kaatz, G. W. (1991). Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrobial Agents and Chemotherapy 35, 1089-92.
33. Perl, T. M., Pfaller, M.A., Houston, A. et al. (1990). Effect of serum on the in vitro activities of 11 broad-spectrum antibiotics. Antimicrobial Agents and Chemotherapy 34, 2234-9.
34. Woodworth, J. R., Nyhart, E. H., Jr, Brier, G. L. et al. (1992). Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrobial Agents and Chemotherapy 36, 318-25.
35. Liu, X. D. & Chen, J. (2001). Prediction of drug clearance in humans from laboratory animals based on body surface area. European Journal of Drug Metabolism and Pharmacokinetics 26, 249-55.
36. Wurtz, R., Itokazu, G. & Rodvold, K. (1997). Antimicrobial dosing in obese patients. Clinical Infectious Diseases 25, 112-8.
37. Venkatakrishnan, K., Von Moltke, L. L. & Greenblatt, D. J. (2001). Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology 41, 1149-79.
38. Hochman, J. H., Yamazaki, M., Ohe, T. et al. (2002). Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Current Drug Metabolism 3, 257-73.
39. Walker, R., Andes, D., Conklin, R. et al. (1994). Pharmacodynamic activities of meropenem in an animal model. In Program and Abstracts of the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, USA, 1994. Abstract 91. American Society for Microbiology, Washington, DC, USA.